Methods for, among other things, improving sleep, energy and social interaction and reducing concern or worry in mammals are provided. In one embodiment, the method includes administering a tablet, capsule or caplet of 190 mg to 3200 mg of compositions that include extracts of Crateva nurvala, Equisetum arvense, Lindera aggregata, and Zea mays daily.

Methods for, among other things, improving sleep, energy and social interaction and reducing concern or worry in mammals are provided. In one embodiment, the method includes administering a tablet, capsule or caplet of 190 mg to 3200 mg of compositions that include extracts of Crateva nurvala, Equisetum arvense, Lindera aggregata, and Zea mays daily.

Methods for, among other things, improving sleep, energy and social interaction and reducing concern or worry in mammals are provided. In one embodiment, the method includes administering a tablet, capsule or caplet of 190 mg to 3200 mg of compositions that include extracts of Crateva nurvala, Equisetum arvense, Lindera aggregata, and Zea mays daily.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

This invention discloses a herbal composition for treating or preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including the wild type and its different variant strains. The composition comprises the extract of Platycodon grandiflorum, which showed the synergistic inhibitory effect of infection compared to the Anti-epidemic No. 1 (AN1) consisted of Astragalus membranaceus, Atractylodes macrocephala, Saposhnikovia divaricata, Atractylodes lancea, Pogostemon cablin, Glehnia littoralis, Lonicera japonica and Cyrtomium fortunei.

An antidepressant food and a method for preparing the same are provided. The antidepressant food includes, by mass percentage, Semen ziziphi spinosae powder in a range of 28% to 36%, γ-aminobutyric acid in a range of 10% to 15%, theanine in a range of 15% to 20%, phosphatidylserine in a range of 10% to 20%, Ficus tikoua extract in a range of 8% to 14%, Huperzia serrata extract in a range of 10% to 16%, sucralose in a range of 0.5% to 1% and fruit essence in a range of 0.5% to 1.5%.

An antidepressant food and a method for preparing the same are provided. The antidepressant food includes, by mass percentage, Semen ziziphi spinosae powder in a range of 28% to 36%, γ-aminobutyric acid in a range of 10% to 15%, theanine in a range of 15% to 20%, phosphatidylserine in a range of 10% to 20%, Ficus tikoua extract in a range of 8% to 14%, Huperzia serrata extract in a range of 10% to 16%, sucralose in a range of 0.5% to 1% and fruit essence in a range of 0.5% to 1.5%.

The present invention relates to compositions containing a pterosin compound and derivatives thereof as active ingredients for the prevention or treatment of degenerative brain diseases and, more specifically, to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases and a food composition for the prevention or alleviation of degenerative brain diseases, each of which contains a pterosin compound defined by chemical formula 1 or a derivative thereof as an active ingredient. A method of the present invention can be favorably used to provide a therapeutic agent for preventing or treating degenerative brain diseases, a food for alleviating degenerative brain diseases, or a functional food for the promotion of cognitive functions, by using a pterosin compound extracted from Pteridium aquilinum and derivatives thereof.

The present invention relates to compositions containing a pterosin compound and derivatives thereof as active ingredients for the prevention or treatment of degenerative brain diseases and, more specifically, to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases and a food composition for the prevention or alleviation of degenerative brain diseases, each of which contains a pterosin compound defined by chemical formula 1 or a derivative thereof as an active ingredient. A method of the present invention can be favorably used to provide a therapeutic agent for preventing or treating degenerative brain diseases, a food for alleviating degenerative brain diseases, or a functional food for the promotion of cognitive functions, by using a pterosin compound extracted from Pteridium aquilinum and derivatives thereof.